BioCentury | Mar 7, 2020
Emerging Company Profile

Kira: depleting activated dendritic cells

...Clark and Hart reported that depleting activated dendritic cells with a human antibody against CD83...
...cell transplant (HCT), while maintaining T cell immunity. Baker declined to disclose whether KB312 targets CD83...
...tyrosine kinase JAK-1 - Janus kinase-1 JAK-2 - Janus kinase-2 Hongjiang Li, Staff Writer Bruton's tyrosine kinase (Btk) CD83 Janus...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...as an autoimmune target that is emerging as a lever for manipulating the microbiome, and CD83...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

...results for that parameter ( No. 2128 , No. 4581 ). The antigen presentation regulator CD83...
...study conducted by academics ( No. 4539 ). BCIQ contains no companies with programs targeting CD83...
...A/S Memorial Sloan Kettering Cancer Center Miltenyi Biotec GmbH Nationwide Children's Hospital Nordic Nanovector ASA Pfizer Inc. University of Minnesota University of Oslo CD37 CD83 Killer...
BioCentury | Aug 19, 2013
Clinical News

Argos, Danaher preclinical data

...Immunology. Argos has exclusive rights from Beckman Coulter Inc. to develop and commercialize the soluble CD83...
...1, 2006). Argos Therapeutics Inc. , Durham, N.C. Danaher Corp. (NYSE:DHR), Washington, D.C. Product: Soluble CD83...
BioCentury | May 16, 2011
Clinical News

Argos, Beckman Coulter preclinical data

...in Philadelphia. Argos has an exclusive license from Beckman to develop and commercialize the soluble CD83...
...2006). Argos Therapeutics Inc. , Durham, N.C. Beckman Coulter Inc. (NYSE:BEC), Brea, Calif. Product: Soluble CD83...
BioCentury | Apr 30, 2009
Distillery Therapeutics

Indication: Renal disease

...additional kidney disease models and in human biopsy samples. Argos Therapeutics Inc. has a soluble CD83...
...treat autoimmune diseases. The Mater Medical Research Institute's RA83, a rabbit polyclonal antibody targeting human CD83...
BioCentury | Mar 16, 2009
Clinical News

Argos, Beckman Coulter preclinical data

...in Alberta. Argos has an exclusive license from Beckman to develop and commercialize the soluble CD83...
...2006). Argos Therapeutics Inc. , Durham, N.C. Beckman Coulter Inc. (NYSE:BEC), Fullerton, Calif. Product: soluble CD83...
BioCentury | Feb 19, 2009
Cover Story

Dendritic cell depletion for acute GvHD

...recombinant soluble CD83 protein or anti-CD83 antibodies, represent a new treatment paradigm," he said. Tolerating CD83...
...to achieve a sustained blockade of CD83. The problem is that a prolonged blockade of CD83...
...CD83-targeting antibodies. She said this would include evaluating DC immunocompetence in the presence of the anti-CD83...
BioCentury | Feb 12, 2009
Distillery Therapeutics

Indication: Transplantation

...in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Transplantation Graft-versus-host disease (GvHD) CD83...
...GvHD. In a mouse model of GvHD, RA83, an antibody targeting the DC activation marker CD83...
...from Genzyme Corp., is marketed for the same indication. Argos Therapeutics Inc. has a soluble CD83...
BioCentury | Aug 7, 2008
Targets & Mechanisms

Avoiding TB's subversion

...be detected by morphological changes and the appearance of surface markers such as CD80 and CD83...
Items per page:
1 - 10 of 14